Analysts expect Inogen, Inc. (NASDAQ:INGN) to report $76.20 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Inogen’s earnings, with the highest sales estimate coming in at $76.40 million and the lowest estimate coming in at $76.00 million. Inogen posted sales of $73.98 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 3%. The company is expected to report its next quarterly earnings results on Wednesday, February 23rd.
On average, analysts expect that Inogen will report full year sales of $356.69 million for the current year, with estimates ranging from $355.72 million to $358.00 million. For the next financial year, analysts anticipate that the company will report sales of $373.19 million, with estimates ranging from $354.60 million to $382.03 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Inogen.
Inogen (NASDAQ:INGN) last announced its earnings results on Thursday, November 4th. The medical technology company reported $0.53 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.82. Inogen had a net margin of 3.21% and a return on equity of 3.11%. The firm had revenue of $93.11 million for the quarter, compared to analyst estimates of $86.69 million. During the same quarter in the prior year, the business posted ($0.08) EPS. The business’s revenue was up 25.3% compared to the same quarter last year.
A number of large investors have recently bought and sold shares of the business. Mutual of America Capital Management LLC grew its holdings in Inogen by 7.1% in the second quarter. Mutual of America Capital Management LLC now owns 2,642 shares of the medical technology company’s stock worth $172,000 after purchasing an additional 176 shares during the period. CWM Advisors LLC grew its holdings in shares of Inogen by 2.8% during the second quarter. CWM Advisors LLC now owns 6,884 shares of the medical technology company’s stock valued at $449,000 after buying an additional 189 shares during the last quarter. Handelsbanken Fonder AB grew its holdings in shares of Inogen by 4.6% during the third quarter. Handelsbanken Fonder AB now owns 6,865 shares of the medical technology company’s stock valued at $296,000 after buying an additional 300 shares during the last quarter. Swiss National Bank grew its holdings in shares of Inogen by 0.7% during the third quarter. Swiss National Bank now owns 42,000 shares of the medical technology company’s stock valued at $1,810,000 after buying an additional 300 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its holdings in shares of Inogen by 3.8% during the second quarter. State Board of Administration of Florida Retirement System now owns 9,015 shares of the medical technology company’s stock valued at $588,000 after buying an additional 332 shares during the last quarter. Institutional investors and hedge funds own 93.10% of the company’s stock.
Shares of NASDAQ INGN traded down $0.16 during trading hours on Friday, hitting $30.80. 146,696 shares of the stock were exchanged, compared to its average volume of 254,388. The company has a market cap of $699.90 million, a PE ratio of 62.86 and a beta of 0.97. The company’s fifty day simple moving average is $32.95 and its two-hundred day simple moving average is $49.17. Inogen has a 1-year low of $26.19 and a 1-year high of $82.35.
Inogen, Inc engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products consists of Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home.
Recommended Story: What is the Dividend Aristocrat Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.